These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21122646)

  • 21. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.
    Andrikoula M; McDowell IF
    Diabetes Obes Metab; 2008 Apr; 10(4):271-8. PubMed ID: 18333887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum trypsin-like activity in chronic alcoholized men: possible relationship with lipids, apoA-1 and apoB lipoproteins.
    Joly JP; Sesboüe R; Hillemand B; Martin JP
    Alcohol Alcohol; 1992 Sep; 27(5):563-9. PubMed ID: 1476559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Role of biochemical risk factors and markers for the risk of atherosclerosis].
    Montagnana M; Lippi G; Salvagno GL; Franchini M; Targher G; Guidi GC
    Recenti Prog Med; 2008 Apr; 99(4):215-22. PubMed ID: 18595637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study.
    Juonala M; Viikari JS; Kähönen M; Solakivi T; Helenius H; Jula A; Marniemi J; Taittonen L; Laitinen T; Nikkari T; Raitakari OT
    J Am Coll Cardiol; 2008 Jul; 52(4):293-9. PubMed ID: 18634985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apolipoproteins A-I and B-markers in coronary risk evaluation.
    Agoston-Coldea L; Zdrenghea D; Pop D; Crăciun A; Rusu ML; Mocan T
    Rom J Intern Med; 2007; 45(3):251-8. PubMed ID: 18333357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipids for psychiatrists - an overview.
    Young IS
    J Psychopharmacol; 2005 Nov; 19(6 Suppl):66-75. PubMed ID: 16280339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Determination of apolipoproteins: An important tool for prevention and treatment of cardiovascular diseases].
    Wiklund O
    Lakartidningen; 2007 May 14-29; 104(20-21):1623-4. PubMed ID: 17564272
    [No Abstract]   [Full Text] [Related]  

  • 28. [Evaluation of selected risk factors of atherosclerosis in children with type 1 diabetes mellitus and hypercholesterolemia].
    Muchacka-Bianga M; Deja G; Jarosz-Chobot P; Małecka-Tendera E; Kalina M; Grychtoł M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(1):25-30. PubMed ID: 16704858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipids, biomarkers, and noninvasive imaging of atherosclerotic disease activity in clinical trials.
    McCullough PA; Lepor NE
    Rev Cardiovasc Med; 2008; 9(2):142-9. PubMed ID: 18660735
    [No Abstract]   [Full Text] [Related]  

  • 30. ApoB/ApoA-I ratio in young patients with ischemic cerebral stroke or peripheral arterial disease.
    Sabino AP; De Oliveira Sousa M; Moreira Lima L; Dias Ribeiro D; Sant'Ana Dusse LM; Das Graças Carvalho M; Fernandes AP
    Transl Res; 2008 Sep; 152(3):113-8. PubMed ID: 18774540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study.
    Sattar N; Williams K; Sniderman AD; D'Agostino R; Haffner SM
    Circulation; 2004 Oct; 110(17):2687-93. PubMed ID: 15492304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apolipoprotein B and non-high-density lipoprotein cholesterol are better risk markers for coronary artery disease than low-density lipoprotein cholesterol in hypertriglyceridemic metabolic syndrome patients.
    Boumaiza I; Omezzine A; Rejeb J; Rebhi L; Kalboussi N; Ben Rejeb N; Nabli N; Ben Abdelaziz A; Boughazala E; Bouslama A
    Metab Syndr Relat Disord; 2010 Dec; 8(6):515-22. PubMed ID: 20715933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein A1 and B.
    Sniderman AD; Marcovina SM
    Clin Lab Med; 2006 Dec; 26(4):733-50. PubMed ID: 17110237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigens and granularity of blood monocytes in relation to inflammatory markers and lipids in postmenopausal women.
    Zouaoui Boudjeltia K; Gregoir C; Guillaume M; Remacle C; Piro P; Garbar C; Ducobu J; Moguilevsky N; Vanhaeverbeek M; Delree P; Brohee D
    Maturitas; 2006 Sep; 55(2):132-41. PubMed ID: 16464548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy.
    Feeman WE
    Circulation; 2003 May; 107(20):e199. PubMed ID: 12777330
    [No Abstract]   [Full Text] [Related]  

  • 36. Better heart attack prediction from new cholesterol test? Two simple tests could someday elbow aside, or at least complement, today's standard cholesterol tests.
    Harv Heart Lett; 2006 Jun; 16(10):3. PubMed ID: 16791941
    [No Abstract]   [Full Text] [Related]  

  • 37. Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease.
    Faergeman O
    J Intern Med; 2006 May; 259(5):434-6. PubMed ID: 16629848
    [No Abstract]   [Full Text] [Related]  

  • 38. Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy.
    Denke MA
    Circulation; 2005 Nov; 112(22):3368-70. PubMed ID: 16316961
    [No Abstract]   [Full Text] [Related]  

  • 39. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is..
    Sniderman AD
    Circulation; 2005 Nov; 112(22):3366-7. PubMed ID: 16316960
    [No Abstract]   [Full Text] [Related]  

  • 40. Screening and follow-up of infants with dyslipoproteinemia.
    Roseneu M; Van Biervliet JP
    Prog Clin Biol Res; 1985; 188():79-86. PubMed ID: 3933016
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.